Evaluation of Efficacy and Safety of KW-136 Plus Sofosbuvir for Treatment-naive Adults Chronically Infected With Hepatitis C Virus: a Randomized, Open-label, Multicenter Phase 2 Trial

Trial Profile

Evaluation of Efficacy and Safety of KW-136 Plus Sofosbuvir for Treatment-naive Adults Chronically Infected With Hepatitis C Virus: a Randomized, Open-label, Multicenter Phase 2 Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs KW-136 (Primary) ; Sofosbuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms KW-136_II
  • Sponsors Beijing Kawin Technology Share-Holding
  • Most Recent Events

    • 06 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top